Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07023822 · ClinicalTrials.gov registry record · NA

WISH, Feasibility of a Factorial Design

A NA study of Breast Cancer and Body Image, sponsored by The University of Tennessee, Knoxville.

Active
Registry status
NA
Development phase
18
Enrollment target
1
Study location

NCT07023822: Active NA study of Breast Cancer and Body Image, sponsored by The University of Tennessee, Knoxville.

NCT07023822 is a NA study of Breast Cancer and Body Image that is active but no longer recruiting, run by The University of Tennessee, Knoxville. The registered enrollment target is 18 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07023822, a NA study of Breast Cancer and Body Image, is active but no longer recruiting, sponsored by The University of Tennessee, Knoxville.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

The primary aim of this study is to evaluate the feasibility of testing a multi-component intervention for sexual function using a factorial design.

Primary Outcome

The number of women who consented to participate in the study divided by the number who were eligible and educated about the study.

Interventions

  • DEVICE Hyaluronic acid (HLA) Vaginal Moisturizer
  • DEVICE Polycarbophil Vaginal Moisturizer
  • BEHAVIORAL Hypnotic Relaxation
  • BEHAVIORAL Progressive Muscle Relaxation (PMR)

Study Locations (1)

Tennessee

  • University of Tennessee, College of Nursing - Knoxville

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2025-06-16
Est. Completion 2025-09-30
Phase NA

What the registry record for NCT07023822 still lists

NCT07023822 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Hyaluronic acid (HLA) Vaginal Moisturizer is the first listed.

NCT07023822 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT07023822 about?

NCT07023822 is a clinical study titled "WISH, Feasibility of a Factorial Design". The primary aim of this study is to evaluate the feasibility of testing a multi-component intervention for sexual function using a factorial design.

What is the current status of trial NCT07023822?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 18 participants. The study started on 2025-06-16. Estimated completion is 2025-09-30.

What conditions does trial NCT07023822 study?

This clinical trial studies the following conditions: Breast Cancer, Body Image, Vulvovaginal Signs and Symptoms, Sexual Desire Disorder.

What interventions are being tested in trial NCT07023822?

The interventions under investigation include: Hyaluronic acid (HLA) Vaginal Moisturizer (DEVICE), Polycarbophil Vaginal Moisturizer (DEVICE), Hypnotic Relaxation (BEHAVIORAL), Progressive Muscle Relaxation (PMR) (BEHAVIORAL).

Who is sponsoring clinical trial NCT07023822?

This trial is sponsored by The University of Tennessee, Knoxville, which has 81 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07023822 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07023822's enrollment target sits among peer trials

18 1118th of 1224 higher than 97 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07023822, the US trial registry maintained by the National Library of Medicine. NCT07023822 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.